>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
组蛋白去乙酰化酶11的表达在霍奇金淋巴瘤中的临床病理意义初探
作者:黄仁宏  胡丽娜  王筱媛  曹婷  乔振东  闵志均  余明华  刘晓健 
单位:复旦大学附属浦东医院科研与创新中心, 上海 201399
关键词:经典霍奇金淋巴瘤 组蛋白去乙酰化酶11 临床病理特征 预后 
分类号:R733.4
出版年·卷·期(页码):2018·37·第二期(204-209)
摘要:

目的:探讨经典霍奇金淋巴瘤(classical Hodgkin lymphoma,cHL)组蛋白去乙酰化酶(histone deacetylase,HDAC)11的表达及其与临床病理特征和预后的关系。方法:应用免疫组织化学方法检测56例cHL患者肿瘤组织中HDAC11的表达情况,并研究其与临床病理特征及预后的关系。结果:全组霍奇金-李-斯(Hodgkin-Reed-Steinberg,HRS)细胞中HDAC11的表达14例阴性、28例弱阳性和14例阳性,结节硬化型共28例,高表达率21.4%;混合细胞型共22例,高表达率27.2%。HDAC11在cHL的组织HRS细胞中的表达与性别、年龄、肿瘤分期、大肿块及B症状的关系不明显,与是否有结外累犯有明显关联(χ2=8.185,P=0.011)。56例cHL患者中位无进展生存期(progression free survival,PFS)为140个月(95% CI为90.1~189.9)、总生存期(overall survival,OS)为108个月(95% CI为96.0~119.9)。HDAC11阴性表达组的10年PFS大于HDAC11弱阳性组,也大于HDAC11阳性组(分别为86%、70%和15%),两两比较差异有统计学意义(Log-rank检验P=0.013);HDAC11阴性组的10年OS大于HDAC11弱阳性组,也大于HDAC11阳性组(分别为100%、78%和45%),两两比较差异有统计学意义。结论:HDAC11表达与cHL患者是否有结外累犯有关,与其他临床病理特征无关,HDAC11低表达是普遍现象,HDAC11表达增高与PFS及OS呈负相关。

Objective:To investigate the expression of histone deacetylase(HDAC) 11 in classical Hodgkin lymphoma (cHL) and its relationship with clinicopathological features and prognosis. Methods:I mmunohistochemistry was used to detect the expression of HDAC11 in tumor tissues from 56 cHL patients and further studied the relationship between the HDAC11 expression and clinicopathological features and prognosis. Results:Among all patients, 14 cases were negative expression of HDAC11, 28 cases weakly positive and 14 cases positive. In 28 cases of nodular sclerosis type, the high expression rate was 21.4%; in a total of 22 cases of mixed cell type, the high expression rate of 27.2%. The relationship between HDAC11 expressions of Hodgkin-Reed-Steinberg (HRS) in cHL tissue and the gender, age, stage, bulky disease and B symptoms were not significantly differences. The HDAC11 expression had a significant correlation to the extranodal infiltration(χ2=8.185, P=0.011). The median progression free survial(PFS) was 140 months(95% CI 90.1-189.9) and overall survival(OS) was 108 months(95% CI 96.0-119.9) in all 56 patients with cHL. Ten years PFS of HDAC 11 negative expression group was 86%, was more than that of HDAC 11 weak positive group(70%) and that of the HDAC11 positive expression group (15%), the difference was statistically significant (Log-rank P=0.013). Ten years OS of HDAC 11 positive expression group was 100%, was more than that of HDAC weak positive group(78%) and that of HDAC 11 negative expression group(45%), the difference was statistically significant. Conclusion:The expression of HDAC11 relates to the presence of the extranodal infiltration in cHL patients, and is not associated with other clinicopathological features. The low expression of HDAC11 is a co mmon phenomenon. The increased expression of HDAC11 is negatively correlated with PFS and OS in patients with cHL.

参考文献:

[1] 李小秋,李甘地,高子芬,等.中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J].诊断学理论与实践,2012,11(2):111-115.
[2] 汤士芳,余利,祁静.个案管理在淋巴瘤患者治疗与康复护理中的应用研究[J].现代医学,2014,42(8):950-952.
[3] ANSELL S M.Hodgkin lymphoma:2016 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2016,91(4):434-442.
[4] PERRI F,LONGO F,GIULIANO M,et al.Epigenetic control of gene expression:Potential implications for cancer treatment[J].Critical Reviews in Oncology Hematology,2017,111:166-172.
[5] TERRANOVA-BARBERIO M,THOMAS S,MUNSTER P N.Epigenetic modifiers in immunotherapy:a focus on checkpoint inhibitors[J].Immunotherapy,2016,8(6):705-719.
[6] ADAMS H,FRITZSCHE F R,DIRNHOFER S,et al.Class I histone deacetylases 1,2 and 3 are highly expressed in classical Hodgkin's lymphoma[J].Expert Opinion on Therapeutic targets,2010,14(6):577-584.
[7] GLASER S L,CHANG E T,CLARKE C A,et al.Hodgkin lymphoma incidence in ethnic enclaves in California[J].Leukemia & lymphoma,2015,56(12):3270-3280.
[8] MULLER B M,JANA L,KASAJIMA A,et al.Differential expression of histone deacetylases HDAC1,2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression[J].BMC Cancer,2013,13:215.
[9] MARQUARD L,GJERDRUM L M,CHRISTENSEN I J,et al.Prognostic significance of the therapeutic targets histone deacetylase 1,2,6 and acetylated histone H4 in cutaneous T-cell lymphoma[J].Histopathology,2008,53(3):267-277.
[10] 龙启来,林锐,杨渊峰,等.组蛋白去乙酰化酶在前列腺癌组织中表达的意义[J].中华泌尿外科杂志,2011,32(9):603-606.
[11] KRISHNA S,KUMAR V,SIDDIQI M I.Recent advances in computer-assisted structure-based identification and design of histone deacetylases inhibitors[J].Current Topics in Medicinal Chemistry,2016,16(9):934-947.
[12] GLOGHINI A,BUGLIO D,KHASKHELY N M,et al.Expression of histone deacetylases in lymphoma:implication for the development of selective inhibitors[J].Br J Haematol,2009,147(4):515-525.
[13] BUGLIO D,KHASKHELY N M,VOO K S,et al.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma[J].Blood,2014,124(3):464-465.
[14] MOYAL L,FELDBAUM N,GOLDFEIZ N,et al.The therapeutic potential of AN-7,a novel histone deacetylase inhibitor,for treatment of mycosis fungoides/sezary syndrome alone or with doxorubicin[J].PLoS One,2016,11(1):e0146115.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 143242 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364